Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Foretinib
Другие языки:

    Foretinib

    Подписчиков: 0, рейтинг: 0
    Foretinib
    Foretinib.svg
    Names
    Preferred IUPAC name
    N1-[3-Fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-N′1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
    Other names
    XL880; EXEL-2880; GSK1363089; GSK089
    Identifiers
    3D model (JSmol)
    ChEBI
    ChEMBL
    ChemSpider
    DrugBank
    ECHA InfoCard 100.158.129
    KEGG
    PubChem CID
    UNII
    • Key: CXQHYVUVSFXTMY-UHFFFAOYSA-N
    • InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
    • COc1cc2c(ccnc2cc1OCCCN3CCOCC3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
    Properties
    C34H34F2N4O6
    Molar mass 632.665 g·mol−1
    Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

    Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by Exelixis and is under development by GlaxoSmithKline. About 10 Phase II clinical trials have been run. As of October 2015 it appears development has been discontinued.

    Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).

    See also


    Новое сообщение